<SEC-DOCUMENT>0001213900-21-031359.txt : 20210608
<SEC-HEADER>0001213900-21-031359.hdr.sgml : 20210608
<ACCEPTANCE-DATETIME>20210608091527
ACCESSION NUMBER:		0001213900-21-031359
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20210608
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210608
DATE AS OF CHANGE:		20210608

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Citius Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001506251
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				273425913
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38174
		FILM NUMBER:		211001361

	BUSINESS ADDRESS:	
		STREET 1:		11 COMMERCE DRIVE
		STREET 2:		1ST FLOOR
		CITY:			CRANFORD
		STATE:			NJ
		ZIP:			07016
		BUSINESS PHONE:		(908) 967-6676

	MAIL ADDRESS:	
		STREET 1:		11 COMMERCE DRIVE
		STREET 2:		1ST FLOOR
		CITY:			CRANFORD
		STATE:			NJ
		ZIP:			07016

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Trail One, Inc.
		DATE OF NAME CHANGE:	20110314

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TrailOne, Inc.
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ea142344-8k_citius.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">UNITED STATES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">SECURITIES AND EXCHANGE COMMISSION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">Washington, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">__________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">__________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.2in 0 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">CURRENT REPORT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">Pursuant to Section 13 or 15(d) of</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">the Securities Exchange Act of 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">Date of Report (Date of earliest event reported) <U>June
8, 2021</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">__________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B><U>Citius Pharmaceuticals, Inc.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Exact name of registrant as specified in its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">__________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><U>Nevada</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">(State or other jurisdiction of incorporation)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;&#9;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="border-bottom: Black 1pt solid; text-align: center; padding-left: 10pt; width: 40%">&nbsp;333-206903</TD>
  <TD STYLE="width: 20%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; padding-left: 10pt; width: 40%">&#9; &#9; 27-3425913<U>&#9;</U></TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: center; padding-left: 10pt">(Commission File Number)</TD>
  <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-left: 10pt">(IRS Employer Identification No.)&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; border-bottom: black 1pt solid; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11 Commerce Drive, 1st Floor, Cranford, NJ</FONT></TD>
    <TD STYLE="width: 20%">&nbsp;</TD>
    <TD STYLE="width: 40%; border-bottom: black 1pt solid; text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">07016</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address of principal executive offices)</FONT></TD>
    <TD STYLE="text-align: center; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: center; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip Code)</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">Registrant's telephone number, including area code
<U>(908) 967-6677 </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">__________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.2in 0 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.2in 0 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.2in 0 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities registered pursuant to Section 12(b) of the Act:&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>




<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; width: 32%">
    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">Title of each class</P></TD>
    <TD STYLE="width: 1.5%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; width: 32%">
    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">Trading Symbol(s)</P></TD>
    <TD STYLE="width: 1.5%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; width: 32%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">Name of each exchange</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">on
    which registered</P></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">Common stock, $0.001 par value</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">CTXR</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">The Nasdaq Capital Market</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">Warrants to purchase common stock</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">CTXRW</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">The Nasdaq Capital Market</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.2in 8pt 0pt; text-align: left">Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.2in 8pt 0pt; text-align: left">Emerging growth company &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.2in 8pt 0pt; text-align: left">If an emerging growth company, indicate by check mark
if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.2in 8pt 0.25in">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.2in 8pt 0.25in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Item 8.01 Other Events.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 8, 2021, Citius Pharmaceuticals, Inc. issued
a press release announcing that the next planned interim analysis in its Phase 3 trial of Mino-Lok&reg;, an antibiotic lock solution for
the treatment of patients with catheter-related blood stream infections, has been scheduled for the end of June 2021. A copy of the press
release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Item 9.01. Financial Statements and Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt -40pt; text-align: left; text-indent: 40pt">(d)&nbsp;<U>Exhibits&nbsp;</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 -40pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt -40pt; text-align: justify; text-indent: 40pt">The following exhibit is filed
herewith:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 15pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid; width: 7%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
    No.</B></FONT></TD>
    <TD STYLE="white-space: nowrap; width: 3%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid; width: 90%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; background-color: white; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="white-space: nowrap; background-color: white">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ea142344-ex991_citius.htm">Press Release dated June 8, 2021.</A></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 6pt; margin-bottom: 0; text-align: center">SIGNATURE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Pursuant to the requirements of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CITIUS PHARMACEUTICALS, INC.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: June 8, 2021</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Myron Holubiak</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Myron Holubiak</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President and Chief Executive Officer</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea142344-ex991_citius.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 66.75pt; width: 225pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Citius Pharmaceuticals Achieves Next Interim Analysis
Milestone in its Mino-Lok<SUP>&reg;</SUP> Phase 3 Trial </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt 0.5in; text-align: center"><I>- Independent Data Monitoring Committee
(DMC) to review Mino-Lok<SUP>&reg; </SUP>safety, superiority, and futility data at upcoming meeting scheduled for June 29, 2021-</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>CRANFORD, N.J.</B>, June 8, 2021 -- Citius Pharmaceuticals, Inc. (&quot;Citius&quot;
or the &quot;Company&quot;) (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class
critical care products with a focus on anti-infective products in adjunct cancer care, unique prescription products and stem cell therapy,
today announced that the next planned interim analysis in its Phase 3 trial of Mino-Lok<SUP>&reg;</SUP>, an antibiotic lock solution for
the treatment of patients with catheter-related blood stream infections (CRBSIs/CLABSIs) has been scheduled for the end of June 2021.
In accordance with the independent Data Monitoring Committee (DMC) charter, the DMC will hold a meeting to review the trial data for safety,
superiority and futility.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&ldquo;We look forward to feedback from the DMC following their review
of the trial data,&rdquo; stated Myron Holubiak, President and Chief Executive Officer of Citius.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">According to the Mino-Lok<SUP>&reg;</SUP> Phase 3 study protocol, the DMC
is responsible for conducting interim analyses when 40%, 50% and 65% of the total number of anticipated events have been observed. The
first two interim analyses were conducted by the DMC in 2019 and 2020, respectively. The next interim analysis meeting of the DMC will
be held on June 29, 2021. At that time, the DMC will review unblinded study data and subsequently provide written recommendations to Citius
within five business days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The Mino-Lok<SUP>&reg;</SUP> Phase 3 pivotal superiority trial is a multi-center,
randomized, open-label, blinded study to determine the efficacy and safety of Mino-Lok<SUP>&reg; </SUP>(MLT), a novel antibiotic lock
therapy that combines minocycline with edetate disodium. The primary endpoint for this study is the time (in days following randomization)
to a catheter failure event between randomization and TOC (Week&nbsp;6) in the Intent-to-Treat (ITT) Population.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0; text-align: left">Approximately 144 subjects diagnosed with CRBSI/CLABSI
and who meet all necessary criteria for the study are randomized in a 1:1 ratio to receive either Mino-Lok<SUP>&reg;</SUP> therapy or
standard of care antibiotic lock therapy. To date, the Company has achieved more than 80% of the expected enrollment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">Subjects in the Mino-Lok<SUP>&reg;</SUP> arm receive
one MLT dose daily with a dwell time of two to four hours for a total of seven doses. For subjects in the Control arm, the investigator
determines the antibiotic used in the lock, dose, dwell time, and number of days of administration based on institutional standards or
Infectious Diseases Society of America (IDSA) guidelines.<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><B></B></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>About Mino-Lok<SUP>&reg;</SUP></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Citius is developing Mino-Lok<SUP>&reg;</SUP>, an antibiotic lock solution
to treat patients with catheter-related blood stream infections that was licensed from The University of Texas MD Anderson Cancer Center.
Citius believes Mino-Lok<SUP>&reg;</SUP> provides a superior alternative to removing and replacing a central venous catheter (CVC), leading
to a reduction in serious adverse events and cost savings to the healthcare system. A multicenter Phase 3 pivotal superiority trial is
currently underway. If approved, Mino-Lok<SUP>&reg;</SUP> would be the first and only FDA-approved treatment that salvages central venous
catheters that cause central line-related blood stream infections.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>About Citius Pharmaceuticals, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Citius is a late-stage biopharmaceutical company dedicated to the development
and commercialization of first-in-class critical care products, with a focus on anti-infectives in adjunct cancer care, unique prescription
products, and stem cell therapy. The Company&rsquo;s lead product candidate, Mino-Lok<SUP>&reg;</SUP>, an antibiotic lock solution for
the treatment of patients with catheter-related bloodstream infections (CRBSIs), is currently enrolling patients in a Phase 3 pivotal
superiority trial. Mino-Lok&reg; was granted Fast Track designation by the U.S. Food and Drug Administration (FDA). Through its subsidiary,
NoveCite, Inc., Citius is developing a novel proprietary mesenchymal stem cell treatment derived from induced pluripotent stem cells (iPSCs)
for acute respiratory conditions, with a near-term focus on Acute Respiratory Distress Syndrome (ARDS) associated with COVID-19. For more
information, please visit www.citiuspharma.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Safe Harbor</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">This press release may contain &quot;forward-looking statements&quot; within
the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made
based on our expectations and beliefs concerning future events impacting Citius. You can identify these statements by the fact that they
use words such as &quot;will,&quot; &quot;anticipate,&quot; &quot;estimate,&quot; &quot;expect,&quot; &quot;plan,&quot; &quot;should,&quot;
and &quot;may&quot; and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's
current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial
condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: our ability
to successfully undertake and complete clinical trials and the results from those trials for our product candidates, including Mino-Lok;
risks relating to the results of research and development activities; uncertainties relating to preclinical and clinical testing; the
early stage of products under development; the estimated markets for our product candidates and the acceptance thereof by any market;
the ability of our product candidates to impact the quality of life of our target patient populations; our need for substantial additional
funds; market and other conditions; risks related to our growth strategy; patent and intellectual property matters; our ability to obtain,
perform under and maintain financing and strategic agreements and relationships; our dependence on third-party suppliers; our ability
to procure cGMP commercial-scale supply; government regulation; competition; as well as other risks described in our SEC filings. These
risks have been and may be further impacted by Covid-19. Accordingly, these forward-looking statements do not constitute guarantees of
future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business
are described in detail in our Securities and Exchange Commission (&ldquo;SEC&rdquo;) filings which are available on the SEC&rsquo;s website
at www.sec.gov, including in our Annual Report on Form 10-K for the year ended September 30, 2020, filed with the SEC on December 16,
2020 and updated by our subsequent filings with the SEC. These forward-looking statements speak only as of the date hereof, and we expressly
disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein
to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based,
except as required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Investor Relations for Citius Pharmaceuticals:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Andrew Scott</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Vice President, Special Projects</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">T: 908-967-6677 x105</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">E: ascott@citiuspharma.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Ilanit Allen</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Vice President, Corporate Communications and Investor Relations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">T: 908-967-6677 x113</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">E: iallen@citiuspharma.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !9 2P# 2(  A$! Q$!_\0
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MJY&2 %.<''(KC-?\?>*;7XT/I4&M7"6"ZI% +<;=NPLH(QCT)KZ/KY,\3_\
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M-X07[1X_T\VB[4-UO5<=$&2?TK722::V.?6FXM/<Z?XA^)M:TOQ6]K8ZC-!
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M2T_6O%^M7AM['4;Z:?:7*)-MX&.>H%>U:Y_R -2_Z]9?_0#7DOPL_P"1N?\
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MAR31+O4ITGCGL+E8VM)T8$2IR0>/8CZUS?Q5^$1\7S_VUHKQ0ZN%"S1R'"7
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
6**** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
